Ligand Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.10 Intrinsic Value $241.36median of 6 methods · middle span $153-$280based on filings through 30 Jun 2026 Market Price $302.74Price as of 1 Oct 2026 OvervaluedIntrinsic value is 20% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $6B Enterprise Value $6.2B Shares Outstanding 22.6M diluted Moat Rating None Next Earnings Date8 Dec 2026 Last ex-dividend2 Jul 2010 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ligand Pharmaceuticals is successfully executing its transition into a high-growth, high-margin biopharmaceutical royalty aggregator. By acquiring diversified royalty portfolios and licensing its proprietary platforms (Captisol and NITRICIL), Ligand avoids the binary clinical risks and heavy capital expenditures typical of traditional biotech firms. The pending $739 million acquisition of XOMA Royalty, expected to close in Q3 2026, represents a transformative milestone that will expand Ligand's portfolio to over 200 assets, add seven commercial products, and provide immediate accretion to adjusted EPS. Backed by strong commercial drivers like Filspari, Ohtuvayre, and Capvaxive, Ligand is well-positioned to deliver compounding long-term value. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$247.00 Mean target$342.82 High · most bullish analyst$390.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $247.0015% Integration delays or regulatory hurdles postpone the closing of the XOMA acquisition. Slower-than-expected market adoption of newly launched partner products (e.g., Ohtuvayre, Zelsuvmi) or a decline in Captisol material sales due to customer ordering patterns limits royalty expansion, keeping performance near the low end of historical ranges. Base CaseCentral scenario $342.8260% Matches the consensus meanLigand achieves its updated 2026 guidance of $270 million to $310 million in total revenue and adjusted EPS of $8.50 to $9.50, supported by steady royalty growth from core assets and a partial-year contribution from the XOMA acquisition. The XOMA transaction closes on schedule in Q3 2026, demonstrating strong operating leverage. Bull CaseUpside scenario $390.0025% Rapid commercial uptake of Filspari in both IgAN and FSGS indications, combined with a seamless integration of XOMA Royalty, drives revenues and adjusted EPS well above the high end of 2026 guidance. Accelerated capital deployment of Ligand's robust cash balance into high-yield late-stage royalties further compounds long-term growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |